Concarlo Holdings, LLC

Concarlo Holdings, LLCM can dramatically increase drug efficacy and diagnostic evaluations for ER/PR+ HER2- patients.  IpY, a cdk inhibitor, specifically addresses drug resistance issues. Concarlo believes that, as a cdk inhibitor, IpY will have efficacy in many difference cancers.

              www.concarlo.com   

Patent Information:
Technology/Start-up ID: